Efficacy of low-molecular-weight heparin on the outcomes of in vitro fertilization/intracytoplasmic sperm injection pregnancy in non-thrombophilic women: a meta-analysis

XIU-LI YANG¹, FEI CHEN¹, XIU-YING YANG² D, GUAN-HUA DU² & YANG XU¹

¹Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, and ²State Key Laboratory of Bioactive Substance and Function of Natural Medicines and Beijing Key Laboratory of Drug Target and Screening Research, Institute of Materia Medica of Peking Union Medical College, Beijing, China

Key words

Low-molecular-weight heparin, in vitro fertilization/intracytoplasmic sperm injection, non-thrombophilia, pregnancy outcomes, randomized controlled trial

Correspondence

Xiu-Ying Yang, State Key Laboratory of Bioactive Substance and Function of Natural Medicines and Beijing Key Laboratory of Drug Target and Screening Research, Institute of Materia Medica of Peking Union Medical College, Beijing, China. E-mail: lucia@imm.ac.cn

Conflict of interest

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

Xiu-Ying Yang and Yang Xu contributed equally to the study.

Please cite this article as: Yang X-L, Chen F, Yang X-Y, Du G-H, Xu Y. Efficacy of low-molecular-weight heparin on the outcomes of in vitro fertilization/ intracytoplasmic sperm injection pregnancy in non-thrombophilic women: a meta-analysis. Acta Obstet Gynecol Scand 2018; 97:1061– 1072.

Received: 2 February 2018 Accepted: 17 April 2018

DOI: 10.1111/aogs.13359

Abstract

Introduction. The aim of our study was to evaluate the effect of low-molecularweight heparin on pregnancy outcomes in women without thrombophilia during in vitro fertilization/intracytoplasmic sperm injection treatment. Material and methods. We searched Pubmed, Web of Science, Embase, Cochrane and CNKI (from inception to 2 February 2018). Our study identified randomized controlled trials or quasi-randomized controlled trials comparing low-molecular-weight heparin subcutaneous treatment with no treatment or only luteal support control. The outcomes included live birth rate, clinical pregnancy rate and miscarriage rate. Results. Five trials, including 935 women receiving in vitro fertilization/intracytoplasmic sperm injection treatment, were included in meta-analyses. There were 458 women receiving low-molecularweight heparin and 477 in the control group. No significant differences for live birth rate, clinical pregnancy rate and miscarriage rate were found between the low-molecular-weight heparin and control groups. Of them, four trials reported live birth rate as an outcome and the risk ratio was 1.13 (95% confidence interval 0.88-1.43, p = 0.34). All five trials reported clinical pregnancy rate as an outcome, the risk ratio was 1.08 (95% confidence interval 0.87–1.32, p = 0.47). Three trials reported miscarriage rate and the risk ratio was 0.58 (95% confidence interval 0.30–1.10, p = 0.09). In women with two or more failed in vitro fertilization/intracytoplasmic sperm injection cycles, the risk ratio of live birth rate was 1.15 and the risk ratio of clinical pregnancy rate was 1.17. In women with three or more failed in vitro fertilization/ intracytoplasmic sperm injection cycles, the risk ratios of live birth rate and clinical pregnancy rate were 1.36 and 1.35, respectively. Conclusions. Our results suggested that low-molecular-weight heparin had no effect on pregnancy success rate in non-thrombophilic women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment. However, to justify the use of low-molecular-weight heparin in clinical practice, multicenter trials are still necessary.

Abbreviations: CPR, clinical pregnancy rate; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; LBR, live birth rate; LMWH, low-molecular-weight heparin; MR, miscarriage rate; RCT, randomized clinical trial; RR, risk ratio.

© 2018 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG), **97** (2018) 1061–1072

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Introduction

Recent innovations in in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) treatment have provided considerable hope to couples with fertility complications. However, the pregnancy success rate of IVF/ ICSI remains very low (1). IVF/ICSI treatment is influenced by various factors, such as age, history of recurrent miscarriage, type of fertility problems, quality and number of embryos, lifestyle, type of protocol, endometrial receptiveness and thrombophilia. A number of therapeutic interventions, such as low-molecular-weight heparin (LMWH)/heparin and aspirin, have been used to improve the success of IVF/ICSI (2,3).

The LMWHs are a class of anticoagulant agents with an average molecular weight <8000 Da. Studies showed that LMWH improves the pregnancy outcomes by modulating many physiological processes required for blastocyst adherence, implantation and trophoblast invasion (2,3). LMWH can be given subcutaneously, causing a more controllable anticoagulant effect and is associated with fewer side effects than other anticoagulant agents. LMWH might also promote placental angiogenesis during the first and second trimesters of pregnancy and promote the expression of VEGF soluble receptor-1 during the first trimester (4,5). Previous favorable effects of LMWH in women with thrombophilia precipitated the use of this drug in those without thrombophilia. However, studies on the effect of LMWH as an adjunct to IVF/ICSI treatment have shown conflicting results. Several studies (6-9) suggested that LMWH has beneficial effects in women with recurrent implantation failure, whereas some other studies showed no evidence of benefits (10,11).

The aim of this systematic review and meta-analysis was to evaluate the role of LMWH subcutaneous administration in pregnancy outcomes in non-thrombophilic women undergoing IVF/ICSI. The outcomes included live birth rate (LBR), clinical pregnancy rate (CPR) and miscarriage rate (MR).

Material and methods

The review protocol was established by two investigators (YXL, YXY) before commencement. This review considered randomized controlled trial studies conducted on the efficacy of LMWH therapy in women undergoing IVF/ICSI without thrombophilia. Information regarding patients, such as number of IVF cycles, age and pregnancy outcomes, were also acquired. We followed the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) in conducting this systematic review (see Supporting Information, Table S1 and S2).

Sources

To identify relevant literature we searched the following online databases: Medline (1950–Feburary 2018), EMBASE (1980-February 2018), Cochrane Central Register of Controlled Trials (2003-February 2018), Web of Science (1990-February 2018), China National Knowledge Infrastructure (CNKI, 1979-February 2018), and Japan Scholarly and Academic Information Navigator (CiNii, 2006-February 2018). There was no geographic restriction. The search strategy was performed without any language restriction, i.e. included all non-English articles with relevance. The search in the CiNii was performed in Japanese, and the search in the CNKI database was performed in Chinese language. Medical subject headings and free words were used to identify the citations for addressing the research question. The focused research questions followed PICO (population, intervention, control, and outcomes). The reference lists of all published articles were searched to collect articles related to the subject (search strategy is shown in the Supporting Information, Table S2).

Study identification and data extraction

Our study focused exclusively on the LMWH subcutaneous administration in non-thrombophilic women. We identified studies that evaluated the effect of LMWH in women undergoing IVF/ICSI on live birth, clinical pregnancy and miscarriage rates. We included randomized clinical trial (RCT) and quasi-RCT studies that compared the use of LMWH (intervention) with placebo or no treatment (control) in women undergoing IVF/ICSI without thrombophilia. Populations with or without recurrent implantation or IVF failures were included. In all included studies, LMWH was given from ovulation induction, oocyte retrieval or at embryo transfer until the detection of fetal heart, 9–12 weeks of pregnancy, or for the entire period of the pregnancy.

Studies were selected in a two-stage process. First, the titles and abstracts were screened independently by two reviewers (YXL, YXY) to meet the predefined criteria. Second, each full-text paper was read to decide whether the inclusion or exclusion criteria were applied (YXL, YXY, CF). In cases of duplicate publication, the most recent or

Key Message

Low-molecular-weight heparin may not improve in vitro fertilization outcomes in non-thrombophilic women. complete manuscripts were used. Any relevant references from the full manuscripts were checked. Any disagreement regarding the inclusion or exclusion criteria was consulted and arbitrated by a third reviewer (GHD and XY).

Of the potentially eligible studies, we included five studies in the total and subgroup analyses. We excluded studies for the following reasons: no placebo control group (for example, aspirin as control); no results related to pregnancy outcomes (for example, pregnancy complications); inclusion of women with thrombophilia (7,12) or other characteristics (for example, age) that would influence the final analysis.

Two reviewers (YXL and YXY) independently searched the relevant publications and extracted relevant data from the validated articles. We defined clearly the data to ensure a standardized data extraction. The quality of each study was assessed using the Jadad scale (13). Two reviewers (CF and XY) completed the quality assessment. We designed a protocol and an ExcEL template according to the criteria for each variable to ensure consistency and meet the objective of the data, and the data were recorded comprehensively. The eligibility of each participant was verified before the data were included. The participants who did not meet the inclusion criteria or did not include the relevant outcomes were excluded. Analyses of the data in the trials were repeated twice to verify the results before their inclusion in the meta-analysis.

Outcome measures

The outcomes of the eligible studies comprised composite outcomes. The primary outcome include LBR, and the secondary outcomes included the CPR and MR. LBR was defined as the number of live births divided by the number of women in a group. MR was defined as the number of miscarriages divided by the number of women in a group before 20 weeks of gestation. CPR was defined as the observation of gestational sac on ultrasound at 5–7 weeks of gestation. Side effects are adverse maternal or fetal outcomes, including serious bloody discharge, preeclampsia during the gestational period and intrauterine growth restriction. These definitions were applied in the included studies and used to calculate the outcomes in this review.

Risk of bias assessment

The risk of bias was assessed for each study by YXL and YXY independently using the Cochrane Collaboration Risk of Bias Tool (14). The criteria of bias included selection bias, performance bias, detection bias, attrition bias, reporting bias and other bias. Review authors' judgments were categorized as "low risk," "high risk" or "unclear risk" of bias. All judgments were given by discussion.

Statistical analysis

Risk ratios (RRs) and the related confidence intervals (CIs) were calculated for each outcome included in the study separately. Presence of publication bias was explored using funnel plots of effect size against standard error. Heterogeneity of the exposure effects was evaluated graphically using forest plots. The data were pooled using a fixed-effects model (15). The REVIEW MANAGER software (RevMan, version 5.3 for Windows, Oxford, UK; The Cochrane Collaboration) was used for statistical analysis. A *p* value \leq 0.05 was considered statistically significant for all analyses.

Results

Study characteristics

A flowchart of our search strategy is shown in Figure 1. After comprehensive assessment of the full-text articles, five papers were included in this review. The characteristics of all included studies are listed in Table 1. All included studies were RCTs or quasi-RCTs, and evaluated the effect of LMWH on the treatment outcomes of IVF. No significant differences in heterogeneity were found between the included studies. The results of the studies were then pooled and used for meta-analysis. In total, 935 IVF/ICSI-treated women were included in the two groups: 458 women received the LMWH treatment and 477 women received the control treatment.

LMWH therapy

All the included studies in this meta-analysis used subcutaneous administration of LMWH in IVF/ICSI-treated women. Studies administered LMWH treatment before the beginning of the stimulation phase of the cycle (10), i.e. on the day of oocyte retrieval (11,16,17) or on embryo transfer day (8). Drug was stopped either with a negative pregnancy test or continued till a positive pregnancy test (8), 2 weeks (17), 9 weeks (16), 12 weeks (11), or until delivery (10). In these clinical trials, the previous assisted reproductive technology number varied from zero (10,16) to at least two times (11,17) or three times (8,11,17).

The dosage of four studies fell in the range of 2500–6400 IU daily (8,10,16,17), and one study used 1 mg/kg/ day, which was approximately equal to 100 IU/mg (11). Two studies (11,17) used enoxaparin (MW 4500), one study (16) used dalteparin sodium (MW 5000), one (10) used parnaparin (MW 5000), and one (8) used LMWH calcium injection (MW 3600–5000).




Figure 1. Flowchart of selection procedure according to PRISMA guidelines. LMWH, low-molecular-weight heparin; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; RCT, randomized controlled trial.

Table 1. Baseline characteristics and treatment of women in the include	d studies.
---	------------

Study (country)	Design	Participants	Intervention	Control	Outcomes
Lodigiani et al. 2017 (Italy) (10)	RCT, single center (n = 266)	With: Idiopathic or primary infertility. Without severe thrombophilia, antiphospholipid autoantibodies and abnormal platelet count	LMWH, 4250 IU <60 kg, 6400 IU >60 kg, daily subcutaneous, starting from ovulation induction until delivery in ART. Age: 18–40 years (n = 135)	No treatment. Age: 18–40 years (n = 131)	lbr, Cpr, ir, mr
Xiong et al. 2015 (China) (8)	RCT, single center (n = 147)	With: three or more failed IVF/ICSI cycles. Without: coagulation disorders (d-dimer test >1.5 mg/L), uterine abnormalities, tubal effusion; combined medical diseases (thyroid dysfunction, etc.)	LMWH, 4100 IU were administered from ET, until detection of the fetal heart. Age: 34. 89 ± 2 . 49 years (n = 65)	Luteal phase support. Age: $35.05 \pm$ 2.79 years (n = 82)	CPR, IR
Berker et al. 2011 (Turkey) (17)	Quasi-RCT, single center (n = 219)	With: two or more failed implantations. Without: Coagulation disorders. (Mutations of factor V Leiden, prothrombin gene, methylene tetrahydrofolate reductase gene, and abnormal levels of anti-cardiolipin immunoglobulin G, immunoglobulin M, lupus anticoagulant, anti-thrombin, protein C and protein S). Uterine abnormalities	Enoxaparin sodium, 4000 IU (40 mg) subcutaneously from the day of oocyte retrieval to 12th week of pregnancy. Age: 31.3 ± 4.9 years (n = 110)	No treatment. Age: 31.2 ± 5 (20–44) years (<i>n</i> = 109)	lbr, Cpr, ir, mr
Noci et al. 2011 (Italy) (16)	RCT, single center (n = 153)	With: First IVF/ICSI cycle. Without: Coagulation disorders (both acquired and inherited thrombophilia). Hormonal or uterine abnormalities	Dalteparin sodium, 2500 IU/day (from the day of oocyte retrieval to week 9 of pregnancy). Age: 34.7 \pm 3.6 years (<i>n</i> = 73)	Control group received only progesterone. Age: 35.1 ± 3.1 years (n = 80)	lbr, Cpr, ir, mr
Urman et al. 2009 (Turkey) (11)	RCT, single center (<i>n</i> = 150)	With: two or more failed IVF/ICSI cycles; Without: Coagulation, hormonal or immunological disorders. Obvious causes of implantation failure; Uterine abnormalities	LMWH, 1 mg/kg/day (from the day after oocyte retrieval to week 12 of pregnancy). Age: 34.0 ± 5.0 years ($n = 75$)	No treatment. Age: 34.8 ± 5.8 years. (n = 75)	CPR, LBR, IR, MR

ART, assisted reproductive technology; CPR, clinical pregnancy rate; ET, embryo transfer; ICSI, intracytoplasmic sperm injection; IR, implantation rate; IVF, in vitro fertilization; LBR, live birth rate; LMWH, low-molecular-weight heparin; MR, miscarriage rate; RCT, randomized clinical trials.

Study population

The participants in this review were from Italy, Turkey and China, respectively. According to our exclusion criteria, a study that uses heparin instead of LMWH as treatment was excluded in this meta-analysis (18). Two studies (7,12) that included women with thrombophilia were excluded. One study (12) was excluded due to evaluation of M2/ANXA5-positive couples, a gene that was closely related to thrombophilia. A study that investigated the intrauterine injection of LMWH was also excluded (19). The characteristics of excluded studies are listed in Table 2. The age range of women included in this meta-analysis was 18–47 years.

Quality assessment and publication bias

The studies were accessed according to the quality assessment (Figure 2). A risk of bias assessment was completed. Overall, three studies (10,11,16) strictly followed the RCT rule for blinding the participants, personnel or outcome assessment. These publications were at a low risk of bias

Sub/countryDegrPancipantsInterentionControlSistardide et al 2017RT, three-center (r = 115)With: two or more failedUMM and predinsione at start of simulation Age:No teament:Sistardide et al 2017RT, three-center (r = 113)With: two or more failedUMM and predinsione at start of simulation Age:No teament:Since et al 2017Retrocenter (r = 113)With: two or more failedUMM and predinsione starts of simulation at start at	,	
RCT, three-center (n = 115) With: two or more failed fresh IVFICS toycles: JS:1 ± 0.7 years (n = 57) Stimulation. Age: N Renospective cohort study, multi-center (n = 13 372) With: IVFICSI women JS:1 ± 0.7 years (n = 57) N N Renospective cohort study, multi-center (n = 13 372) With: IVFICSI women, autoimmue disorders Thirteen adjuvants (Intraipid, steroids, melatorin, comsyme 200, Figuarim, sensition, and oppamine agoins) (n = 1904) N DSsenational cohort study, multi-center (n = 206) With: IVFICSI women, AIXAS S M2 positive were enlisted to the cohort and AIXAS S M2 positive were enlisted to the cohort and multi-center (n = 114) N RCT, single center (n = 100) With: Wr/ICSI women, inherited thromophilia, hormonal AIXAS S M2 positive were enlisted to the cohort and achiening mock ET, just after OPU (2-5 days before ET). RCT, single center (n = 81) With: two or more failed Hepaini 5000 U were administered for 15 days from immunologic disorders LUWMH, dilepaini 5000 U were administered for 15 days from immunologic disorders RCT, single center (n = 81) With: two or more failed Hepaini 5000 U were administered for 15 days from immunologic disorders L RCT, single center (n = 81) With: two or more failed MAWH, dilepaini 5000 U were administered for 15 days from immunologic disorders L RCT, single center (n = 81) <th>Control</th> <th>Exclusion criteria</th>	Control	Exclusion criteria
Retrospective cohort study, multi-center ($n = 13$ 372) With Mr. CSI women autoimmure disorders Dimmone and dynamic finitalipid, steroids, melatorin, multi-center ($n = 13$ 372) Notice of the file of a signification, estosterone, DHEA, growth homone, antibotics, file (file of a signification, estosterone, DHEA, growth homone, and dopamine agoins($n = 1004$) N RCT, single center ($n = 114$) With: NF/ICSI women, multi-center ($n = 114$) With: NF/ICSI women, with: NF/ICSI women, multi-center ($n = 114$) With: NF/ICSI women, multi-center ($n = 100$) N/XA5 hapdotype avoid dopamine agoins($n = 1004$) N RCT, single center ($n = 114$) With: WF/ICSI women, implantations; Without: the net of the net agoins($n = 1003$) N/XA5 MZ positive were enlisted to the cohort and during mock. ET, just fire OPU ($z > 5$ days before ET). N RCT, single center ($n = 100$) With: two or more failed implantations; Without: throughout a dopending agoin ($n = 206$) N/YA5 MZ positive were enlisted for 15 days from treated with intrauterine LMWH (encoaparin at munologic disorders L RCT, single center ($n = 81$) With: two or more failed implantations; Without: throughout an operative study, single center ($n = 50$) With: two or more failed implantations; Without: throughout and through a doper of 1 mg/yg/day were initiated on the implantations. Without: throughout and implantations. Without: throughout and implantations. N N RCT, single center ($n = 50$) With: two or more failed implantations. N/M+ disteparin 5000 U/day Vage: mean age imp	No treatment.	Treatment is not
Retrospective cohort study, multi-center ($n = 13.32$) With: NF/ICSI women Thirteen adjuants (Intralipid, stericids, melatorin, more antibiotis, ICG infusion, aspin, novapamingepand, mere enlisted to the cohort and MIth: NF/ICSI women, autoimmune (acorders Printeen adjuants (Intralipid, stericids, melatorin, econsyme Q10, Filgastim, stotstrone, DHEA, growth novapamingepand, mere enlisted to the cohort and MIth: NF/ICSI women, autoimmune (acorders Not ANXAS haplotype CDservational cohort study, multi-center ($n = 114$) With: NF/ICSI women, ANXAS haplotype Thirteen adjuants (Intralipid, stericids, melatorin, comparing enbyo starsite, Age: 36 yeas ($n = 103$) Not ANXAS haplotype RCT, single center ($n = 114$) With: NF/ICSI women, Mithou: 1000 With: Whot: 200 UVdHY end AVXAS haploty tarsite: Age: 36 yeas ($n = 103$) RCT, single center ($n = 114$) With: Wor or none failed inherited thromobaphila, hormonal inherited thromobaphila, hormonal immunologic disorders Mithou: 200 UVdAy. Age: Res ($n = 59$) RCT, single center ($n = 81$) With: two or none failed inplantations; Withou: ($n = 1107$) Mith: two or none failed Mith: two or none faile	Age. 34 1 + 0 7 vears	and nradnisolona)
Rerospective cohort study, multi-center ($n = 13.322$) With: WF/ICSI women Thinteen adjuvants (Intralipid, steroids, melatonin, coensyme QIO, Figaratim, astosterone, DHEA, growth hormone, antibiotis, FIC infusion, aspin, multi-center ($n = 113.322$) With: WF/ICSI women Observational cohort study, multi-center ($n = 13.322$) With: WF/ICSI women, AIXA5 haplotype Thinteen adjuvants (Intralipid, steroids, melatonin, coensyme QIO, Figaratim, astosterone, DHEA, growth Mithous: Intra-termer ($n = 104$) NMA: MF/ICSI women, Mithous: Intra-termer ($n = 104$) RCT, single center ($n = 114$) With: WF/ICSI women, inherited thrombophila, hormonal inherited and inherited in = 1107) Mithous inherited inherited intervelophila, hormonal inherited inherited inherited inherited i	(n = 58)	Retrospective
Retrospective cohort study, multi-center ($n = 13$, 372) With: WF//CSI women Thirteen adjuvants (Intralipid, steroids, melatonin, comzyme (10, Figyastin, and dopamine agonists) ($n = 1904$) Observational cohort study, multi-center ($n = 206$) W/H.: WF//CSI women, MIH: WF//CSI women, multi-center ($n = 206$) W/H.: WF//CSI women, AIXXAS M2 polotype adheming embyor bracker, Age: 38 yeals ($n = 103$) N CT, single center ($n = 114$) With: WF//CSI women, Without: both acquired and during embyor bracker, Age: 38 yeals ($n = 103$) N RCT, single center ($n = 100$) With: two or more failed implantations; Without: AVXX5 M2 polotype adheming embyor bracker, Age: 38 yeals ($n = 103$) N RCT, single center ($n = 100$) With: two or more failed implantations; Without: AVX45 M2 polotype adheming embyor bracker, Age: 38 yeals ($n = 103$) N RCT, single center ($n = 81$) With: two or more failed With: two or more failed With at a prophylakis dose: 4000 U/day. Age: mean age With: two ad		cohort study
multi-center (n = 13 372) coenzyme O10, Figuratin, estosterone, DHEA, growth hormore, and thormore, and the prophytactic dose of LWMH on a turby, single center (n = 10) With: two or more failed Hearin 5000 U day. Age: the OPU (2-5 days before ET). Age: 28.80 ± 5.17 years (n = 59) In RCT, single center (n = 10) With: two or more failed Hearin 5000 U day. Age: mean age interved for 15 days from the day of occyte pick up. Age: ace and	No treatment	Not RCT;
Observational cohort study, multi-center (n = 206) With: IVF/rSI women, AIXA5 haplotype Domone, antibiotics, MG infusion, aspinin, antis-center (n = 103) Nth: IVF/rSI women, AIXA5 haplotype RCT, single center (n = 114) With: WF/rSI women, Mith: WF/rSI women, With: Wo or more failed Meparin 5000 UJ were administered for 15 days from Implantations; Without: thrombophila, hormonal No RCT, single center (n = 10) With: two or more failed implantations; Without: thrombophila, hormonal Heparin 5000 UJ were administered for 15 days from the day of oocyte pick up. Age: 32.46 ± 5.14 years (n = 50) RCT, single center (n = 81) With: two or more failed implantations. Without: thrombophila, hormonal LMWH, daiteparin 5000 U/day. Age: mean age 39 years (n = 33) RCT, single center (n = 52) With: two or more failed implantations. Without: coagulation disorders LMWH, daiteparin 5000 U/day. Age: mean age 37.1 ± 4.9 years (n = 107) Retrospective comparative study, single center (n = 52) With: two or more failed With: two or more failed With With With ados of 1 mg/sq/sd/sdoseg (i.e. Mith: three or more	(n = 11 468)	thrombophilia
Cbservational cohort study, multi-center ($n = 206$) With: NF/ICSI women, MXA5 haplotype noves matro measuring early and a prophydicit dose of LWWH on ANA55 maplotype Noves matro matro matro matro matro matro matro matro matro transfer with a prophydicit dose of LWWH on achieving embry or transfer. Age: 36 years ($n = 103$) No RCT, single center ($n = 114$) With: NF/ICSI women, Without: both acquired and inherited thrombophila. NNA55 maplotype achieving embry or transfer. Age: 36 years ($n = 103$) In RCT, single center ($n = 114$) With: two or more failed inherited thrombophila. Num, achieving embry or transfer. Age: 36 years ($n = 103$) In RCT, single center ($n = 100$) With: two or more failed implantations. Without: thrombophila, hormonal Hepain 5000 U were administered for 15 days from the day of oocyte pick up. Age: mean age implantations. Without: thrombophila, hormonal I RCT, single center ($n = 81$) With: two or more failed implantations. Without: thrombophila, hormonal J </td <td></td> <td>included</td>		included
Descriptional colori study, multi-center ($n = 206$) With: WFACSI women, MXX5 haptotype ANX45 haptotype Anticited with intrauterine LMWH (enoxaparin sodium) Injected with intrauterine LMWH (enoxaparin sodium) Intrauterine LMWH (enoxaparin sodium) In RCT, single center ($n = 811$) With: two or more failed INF Heparin 5000 U/day. Age: mean age N RCT, single center ($n = 811$) With: two or more failed INF 39 years ($n = 33$) S000 U/day. Age: mean age N ($n = 1107$) With: two or more failed INF 39 years ($n = 33$) Comparative solution is the dot of not cocyte pick up. Age: mean age N <		: - -
multi-center ($n = 206$) ANXA5 haplotype tratted with a prophydact dose of LMWH on achieving embryo transfer. Age: 36 years ($n = 10$) In the control ($n = 10$) RCT, single center ($n = 114$) With-WF/CSI women. hipected with intrauterine LWWH (enosaparin sodium) In during mock ET, just after OPU ($2-5$ days before ET). RCT, single center ($n = 114$) With-ut: both acquired and inherited thrombophila. Age: 28.80 ± 5.17 years ($n = 59$) For a 100 RCT, single center ($n = 100$) With: two or more failed implantations; Without: Heparin 5000 IU were administered for 15 days from the day of oocyte pick up. Age: $n = 39$ L RCT, single center ($n = 81$) With: two or more failed implantations; Without: Heparin 5000 IV day. Age: mean age implantations; Without: P RCT, single center ($n = 81$) With: two or more failed implantations; without: MVH, dalteparin 5000 UV day. Age: mean age implantations; without: P RCT, single center ($n = 81$) With: two or more failed implantation; single center MVH, dalteparin 5000 UV day. Age: mean age implantation; single center P RCT, single center ($n = 52$) Comparative study, single center S S S S S RCT, single center ($n = 52$) Comparative study, single center N/H S	No treatment.	Thrombophilia
RCT, single center ($n = 114$) With: WF/ICSI women. achewing embyro transter, Age: 35 years ($n = 103$) inherited thrombophila. RCT, single center ($n = 114$) With: WF/ICSI women. inherited thrombophila. inherited thrombophila. inherited thrombophila. inherited thrombophila. RCT, single center ($n = 114$) With: two or more failed Heparin 5000 IU were administered for 15 days before ET). Age: 38.00 ± 5.17 years ($n = 59$) RCT, single center ($n = 100$) With: two or more failed Heparin 5000 IU were administered for 15 days from L RCT, single center ($n = 81$) With: two or more failed Heparin 5000 IU were administered for 15 days from L RCT, single center ($n = 81$) With: two or more failed HWWH, dalteparin 5000 UVday. Age: mean age N RCT, single center ($n = 81$) With: two or more failed LWWH, dalteparin 5000 UVday. Age: mean age N RCT, single center ($n = 81$) With: two or more failed M M Administer LWWH (enoxaparin or nadroparin at UVH), alterparin 5000 UVday. Age: mean age N RCT, single center ($n = 52$) With: two or more failed M M Administer LWWH (enoxaparin or nadroparin at UVH), alterparin 5000 UVday. Age: mean age N RCT, single center M SY i ± 4.9 years ($n =$	Age: 36 years	included
RCT, single center ($n = 114$) With: W/T/CSI women. Injected with intraterine LMWH (encorporatin sodium) In Without: both acquired and Writhout: both acquired and uring mock ET, just after OPU ($2-5$ days before ET). RCT, single center ($n = 100$) With: two or more failed Heparin 5000 IU were administered for 15 days from L RCT, single center ($n = 100$) With: two or more failed Heparin 5000 IU were administered for 15 days from L RCT, single center ($n = 100$) With: two or more failed Heparin 5000 IU were administered for 15 days from L RCT, single center ($n = 100$) With: two or more failed Heparin 5000 Ulday. Age: mean age N RCT, single center ($n = 81$) With: two or more failed NF/ LMWH, dalteparin 5000 Ulday. Age: mean age N RCT, single center ($n = 81$) With: two or more failed NF/ J So ass: 4000 U/Jay. Age: mean age N RCT, single center With: two or more failed NF/ J So ass: 4000 U/Jay. Age: mean age N RCT, single center With: two or more failed NF/ LMWH, dalteparin 5000 U/day. Age: mean age N RCT, single center With: two or more failed NF/ J Administer LMWH (encovaparin or nadroparin at N R	(n = 103)	
Mithout both acquired and during mock ET, just after OD (2-5 days before ET). an) RCT, single center ($n = 100$) With: two or more failed Hepanin 5000 IU were administered for 15 days from L Acr. Single center ($n = 100$) With: two or more failed Hepanin 5000 IU were administered for 15 days from L RCT, single center ($n = 100$) With: two or more failed Hepanin 5000 Ulday. Age: mean age N implantations. Without: ($n = 50$) With: two or more failed HEVH, dalteparin 5000 Ulday. Age: mean age N roomparative With: two or more failed LWWH, dalteparin 5000 Ulday. Age: mean age N N roomparative With: two or more failed M Administer LMWH (enoxaparin or nadroparin at prophylaxis doses: 4000 IU, 3800 IU and respectively, subcutaneously, once per day by self-injection, aspirin or comparative study, single center N	Injected with a	local intrauterine
Inherited thrombophila. Age: 28.80 \pm 5.17 years (n = 59) Inherited thrombophila. Age: 28.80 \pm 5.17 years (n = 59) Inherited thrombophila. Nith: two or more failed implantations. Without: Age: 28.80 \pm 5.17 years (n = 59) RCT, single center (n = 100) With: two or more failed implantations. Without: Age: 28.80 \pm 5.14 years L RCT, single center (n = 81) With: two or more failed immunologic disorders LWWH, dateparin 5000 Ul/day. Age: mean age N RCT, single center (n = 81) With: two or more failed implantations. Without: Administer LMWH (enoxaparin or nadroparin at 39 years (n = 33) N Prospective comparative study, single center With: two or more failed NF/ (n = 1107) Administer LMWH (enoxaparin or nadroparin at complications without: N Retrospective observational implantation: With: two or more failed NF/ (n = 52) Administer LMWH (enoxaparin or nadroparin at complications until the pregnancy test. Age: thrombophila, hornnoal N Retrospective observational immunologic disorders MWH was administered at a prophylactic dosage (i.e. inplantation: MWH was administered at a prophylactic dosage (i.e. instad and of injections until the pregnancy test. Age: thrombophila, hornnoal MWH was administered at a prophylactic dosage (i.e. instad and properiod disorders MWH was administered at a prophylactic dosage (i.e. inplantation: Retrospective observati	similar volume of	LMWH
Interspective comparative study, single center ($n = 100$) With: two or more failed implantations; Without: Heparin 5000 IU were administered for 15 days from implantations; Without: Age: 3815 ± 4.71 ye sets ($n = 37$) RCT, single center ($n = 81$) With: two or more failed implantations; Without: $(n = 50)$ $(n = 50)$ RCT, single center ($n = 81$) With: two or more failed implantations; Without: $(n = 50)$ $(n = 50)$ RCT, single center ($n = 81$) With: two or more failed implantations; Without: $(n = 50)$ $(n = 50)$ RCT, single center ($n = 81$) With: two or more failed IVF/ Administer LMWH (encwaparin or nadroparin at prophylaxis doses: 4000 UJ, 3800 UJ and respectively, ($n = 50$) $(n = 50)$ RCT, single center ($n = 52$) With: two or more failed IVF/ Administer LMWH (encwaparin or nadroparin at prophylaxis doses: 4000 UJ, 3800 UJ and respectively, ($n = 21$) $(n = 21)$ Retrospective observational With: two or more failed IVF/ Administer LMWH ($(n = 210)$ Mean age: 400 visitions until the pregnancy test. Age: the analysis single center $(n = 52)$ Retrospective observational With: two or more failed IVF/ LMWH was administered at a prophylactic dosage (i.e., No treatment. analysis, single center $(n = 52)$ $(n = 21)$ Retrospective observational With: two or more failed INFH was administered at a prophylactic dosage (tissue culture media.	injections
(n) RCT, single center (n = 100) With: two or more failed inplantations; Without: Hepain 5000 IU were administered for 15 days from tuteal phase intrombophila, hormonal inplantations; Without: 4.79 years (n = 4.71 years support. Age: intrombophila, hormonal immunologic disorders $(n = 50)$ LukuH, dalteparin 5000 IU were administered for 15 days from tuteal phase immunologic disorders $(n = 50)$ RCT, single center (n = 81) With: two or more failed immunologic disorders LukuH, dalteparin 5000 U/day. Age: mean age support. Age: acad with: two or more failed NF Jay wars (n = 33) $(n = 50)$ No treatment. a support. Age: acad NF $(n = 50)$ No treatment. a support. Age: acad NF $(n = 50)$ No treatment. a support. Age: acad NF $(n = 50)$ No treatment. a support. Age: acad NF $(n = 50)$ No treatment. a support. Age: acad NF $(n = 50)$ No treatment. a support. Age: acad NF $(n = 50)$ No treatment. a support. Age: acad NF $(n = 50)$ No treatment. a support. Age: acad NF $(n = 50)$ No treatment. Age: acad NF $(n = 50)$ No treatment. Age: acad NF $(n = 50)$ No treatment. Age: acad NF $(n = 100)$ $(n = 50)$ No treatment. Age: acad NF $(n = 10)$ $(n = 210)$ No treatment. Age: acad NF $(n = 210)$ No treatment. Age: acad NF $(n = 21)$ <th< td=""><td>Age: 28.15 ±</td><td></td></th<>	Age: 28.15 ±	
Interplantations: With: two or more failed Heparin 5000 IU were administered for 15 days from the day of oocyte pick up. Age: 32.46 \pm 5.14 years throun: Implantations: Without: Implantation:	4.79 years $(n = 55)$	
implantations; Without:the day of oocyte pick up. Age: 32.46 \pm 5.14 yearsthrombophilia, hormonalimmunologic disordersRCT, single center ($n = 81$)With: two or more failedWith: two or more failedLMWH, dalteparin 5000 U/day. Age: mean ageNoth: two or more failedUMWH, dalteparin 5000 U/day. Age: mean ageRCT, single center ($n = 81$)With: two or more failedWith: two or more failedWFAdminister LMWHAdminister LMWH (enoxaparin or nadroparin atprospective comparativeWith: two or more failed($n = 1107$)Comparative study, singleComparative study, single centerWith: two or more failed($n = 1107$)Comparative study, single center($n = 52$)With: two or more failedRetrospective observationalWith: two or more failedWith: two or more failedNF/Immunologic disordersIMWH at a dose of 1 mg/gday were initiated on theRetrospective observationalWith: two or more failedWith: two or more failedIMWH was administered at a prophylactic dosage (i.e. $n = 569$)Immunologic disorders($n = 569$)Mith: three or more failed $n = 569$)Mith: three or moreRCT, single centerMith: three or morefailed implantationsMith: three or morefailed inplantationsMith: t	Luteal phase	Treatment is
RCT, single center ($n = 81$)thromologic disordersLMWH, dalteparin 500 Ul/day. Age: mean ageRCT, single center ($n = 81$)With: two or more failedVITH: two or more failedIMWH, dalteparin 5000 Ul/day. Age: mean ageRCT, single center ($n = 81$)With: two or more failedVITH: two or more failedVITH: two or more failedVITH: two or more failedNITH: two or more failedprospective comparativeWith: two or more failedVITH: two or more failedVITH: two or more failedVITH: two or more failedNITH: t	support. Age:	not relevant
RCT, single center $(n = 81)$ immunologic disorders implantations. With: two or more failed implantations. With: two or more failed NF/ coagulation disordersLMWH, dalteparin 5000 U/day. Age: mean age 39 years $(n = 33)$ RCT, single center $(n = 52)$ With: two or more failed NF/ $(n = 1107)$ LMWH, dalteparin 5000 U/day. Age: mean age 39 years $(n = 33)$ Comparative study, single center $(n = 52)$ With: two or more failed NF/ $(n = 1107)$ Administer LMWH (enoxaparin or nadroparin at prophylaxis doses: 4000 U, 3800 U and respectively, subcutaneously, once per day by self-injection), aspirin or combined with LMWH $(n = 210)$ Comparative study, single center $(n = 52)$ With: two or more failed NF/ $(n = 569)$ LMWH at a dose of 1 mg/st/day were initiated on the first day of injections until the pregnancy test. Age: 37.1 ± 4.9 years $(n = 19)$ RcT, single center $(n = 83)$ LMWH was administered at a prophylactic dosage (i.e. enoxaparin 40 mg daily or nadroparin 80/100 U/kg ore daily), starting the day before COH until the day of fig-tcions. until the eary of ph-uman chorionic failed implantationsRcT, single center $(n = 83)$ LMWH was administered at a prophylactic dosage (i.e. enoxaparin 40 mg daily or nadroparin 80/100 U/kg ore daily), starting the day before COH until the day of fig-tcions. Age: more failedRcT, single center $(n = 83)$ With: three or more failedLMWH was administered at a prophylactic dosage (i.e. enoxaparin 40 mg daily or nadroparin 80/100 U/kgRcT, single center $(n = 83)$ With: three or more failedLMWH was administered at a prophylactic dosage (i.e. enoxaparin 40 mg daily or nadroparin 80/100 U/kg	30.9 ± 4.71 years	(Heparin)
RCT, single center ($n = 81$)With: two or more failed implantations. Without:LMWH, dalteparin 5000 U/day. Age: mean age implantations. Without:RCT, single center ($n = 81$)With: two or more failed NF/ implantations. With: two or more failed NF/ implantationsLMWH, dalteparin 5000 U/day. Age: mean age 39 years ($n = 33$)prospective comparative study, single center ($n = 1107$)With: two or more failed NF/ implantationAdminister LMWH (enoxaparin or nadroparin at prophylaxis doses: 4000 U, 3800 U and respectively, subcutaneously, once per day by self-injection), aspirin or combined with LMWH ($n = 210$)Comparative study, single center ($n = 52$)With: two or more failed NF/ immunologic disordersLMWH at a dose of 1 mg/s/day were initiated on the first day of injections until the pregnancy test. Age: 37.1 \pm 4.9 years ($n = 19$)Retrospective observational ($n = 569$)With: two or more failed implantation.LMWH was administered at a prophylactic dosage (i.e. enoxaparin 40 mg daily or nadroparin 80/100 U/kg one daily), starting the day before COH until the day of β-human chorionic ganadotropin testing ($n = 512$)RCT, single center ($n = 83$)With: three or more failed implantationsLMWH was administered at a prophylactic dosage (i.e. enoxaparin 40 mg daily or nadroparin 80/100 U/kg or dalteparin 80/100 U/kg once daily), starting the day before COH until the day of β-human chorionic ganadotropin testing ($n = 512$)RCT, single center ($n = 83$)With: three or more failed implantationsEnoxaparin 40 mg daily or boruna chorionic ganadotropin testing ($n = 512$)	(n = 50)	
implantations. Without:39 years ($n = 33$)coagulation disorderscoagulation disordersprospective comparativeWith: two or more failed NF/prospective comparativeWith: two or more failed NF/ $(n = 1107)$ Mith: two or more failed NF/ $(n = 1107)$ Comparative study, single center $(n = 1107)$ Comparative study, single center $(n = 1107)$ Mith: two or more failed NF/Comparative study, single centerWith: two or more failed NF/ $(n = 52)$ With: two or more failed NF/Comparative study, single centerMith: two or more failed NF/Retrospective observationalWith: two or more failed NF/ $(n = 569)$ Mith: two or more failed implantation.RCT, single center ($n = 83$)Mith: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failed <trt< td=""><td>No treatment.</td><td>Only IR as</td></trt<>	No treatment.	Only IR as
coagulation disorderscoagulation disordersprospective comparativeWith: two or more failed NF/ study, single centerAdminister LMWH (enoxaparin or nadroparin at prophylaxis doses: 4000 U, 3800 IU and respectively, subcutaneously, once per day by self-injection), aspirin or combined with LMWH ($n = 210$)Comparative study, singleWith: two or more failed NF/ to = 1107)Administer LMWH (enoxaparin or nadroparin at prophylaxis doses: 4000 IU, 3800 IU and respectively, subcutaneously, once per day by self-injection), aspirin or combined with LMWH ($n = 210$)Comparative study, singleWith: two or more failed NF/ to = 52)LMWH at a dose of 1 mg/kg/day were initiated on the first day of injections until the pregnancy test. Age: 37.1 \pm 4.9 years ($n = 19$)Retrospective observational immunologic disordersUMWH was administered at a prophylactic dosage (i.e. enoxaparin 40 mg daily or nadroparin 80/100 IU/kg or dalteparin 80/100 IU/kg ore daily), starting the thrombophilia, two or more failed implantationsRCT, single center ($n = 83$)With: three or more failed implantationsRCT, single center ($n = 83$)With: three or more failed implantationsRCT, single center ($n = 83$)With: three or more failed implantations	Mean age:	outcome
prospective comparativeWith: two or more failed IVF/ study, single centerAdminister LMWH (enoxaparin or nadroparin at prophylaxis doses: 4000 IU, 3800 IU and respectively, subcutaneously, once per day by self-injection), aspirin or combined with LMWH ($n = 210$)($n = 1107$)Comparative study, single center ($n = 52$)Mith: two or more failed IVF/ subcutaneously, once per day by self-injection), aspirin or combined with LMWH ($n = 210$)Comparative study, single center ($n = 52$)With: two or more failed IVF/ INTH: two or more failed IVF/ S7.1 ± 4.9 years ($n = 19$)Retrospective observational ($n = 569$)With: two or more failed implantation. Without: both acquired and inherited day before COH until the day of h-uman chorionic failed implantationsRCT, single center ($n = 83$)With: three or more failed implantationsRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failedRCT, single center ($n = 83$)With: three or more failed	40 years $(n = 48)$	
study, single centerICSI cyclesprophylaxis doses: 4000 IU, 3800 IU and respectively, subcutaneously, once per day by self-injection), aspirin or combined with LMWH ($n = 210$)($n = 1107$)Comparative study, singleWith: two or more failed IVF/ or combined with LMWH ($n = 210$)Comparative study, singleWith: two or more failed IVF/ immunologic disordersLMWH at a dose of 1 mg/kg/day were initiated on the first day of injections until the pregnancy test. Age: 37.1 \pm 4.9 years ($n = 19$)Retrospective observational immunologic disordersUMWH was administered at a prophylactic dosage (i.e. enoxaparin 40 mg daily or nadroparin 80/100 IU/kg or dalteparin 80/100 IU/kg onc daily), starting the thrombophilia, two or more failed implantationsRCT, single center ($n = 83$)With: three or more failed implantationsLMWH was administered at a prophylactic dosage (i.e. enoxaparin 40 mg daily or nadroparin 80/100 IU/kg or dalteparin 80/100 IU/kg onc daily), starting the day before COH until the day of β-human chorionic gonadotropin testing ($n = 512$)RCT, single center ($n = 83$)With: three or more failed implantations	No treatment	Not RCT
$(n = 1107)$ subcutaneously, once per day by self-injection), aspirin or combined with LMWH ($n = 210$)Comparative study, singleWith: two or more failed IVF/ or combined with LMWH ($n = 210$)Comparative study, singleWith: two or more failed IVF/ first day of injections until the pregnancy test. Age: 37.1 \pm 4.9 years ($n = 19$)Retrospective observationalWith: two or more failed immunologic disordersRetrospective observationalWith: two or more failed immunologic disordersNotifications until the pregnancy test. Age: immunologic disordersRetrospective observationalWith: two or more failed implantation. Without: both acquired and inheritedNotifications until the day of injections until the day of fi-starting the thrombophilia, two or more failed implantationsRCT, single center ($n = 83$)With: three or more failed implantationsRCT, single center ($n = 83$)With: three or more failed implantationsRCT, single center ($n = 83$)With: three or more failed implantations	(n = 21)	
Comparative study, singleWith: two or more failed IVF/ or contarties with the pregnancy test. Age: ICSI women. Without:UNWH at a dose of 1 mg/kg/day were initiated on the first day of injections until the pregnancy test. Age: 37.1 \pm 4.9 years ($n = 19$)center ($n = 52$)ICSI women. Without: immunologic disorders37.1 \pm 4.9 years ($n = 19$)Retrospective observational analysis, single centerWith: two or more failed implantation. Without: both or dateparin 80/100 IU/kg or daiteparin 80/100 IU/kg or dateparin 80/100 IU/kg or daiteparins 80/100 IU/kg or dateparin 80/100 IU/kg or daiteparins 80/100 IU/kg or dateparin 80/100 IU/kg or daiteparins 80/100 IU/kg or dateparins 80/100 IU/kg or daiteparins 80/100 IU/kg failed implantationsRCT, single center ($n = 83$)With: three or more failed implantationsEnoxaparin 40 mg/day subcutaneous injections. Age:		
Comparative study, singleWith: two or more failed IVHLMWH at a close of 1 mg/kg/day were initiated on the center ($n = 52$)Comparative study, singleICSI women. Without:first day of injections until the pregnancy test. Age: inst day of injections until the pregnancy test. Age: immunologic disordersRetrospective observational37.1 \pm 4.9 years ($n = 19$)Retrospective observationalWith: two or more failedImmunologic disordersLMWH was administered at a prophylactic dosage (i.e. enoxaparin 40 mg daily or nadroparin 80/100 IU/kg($n = 569$)acquired and inheritedacquired and inheritedcu dalteparin 80/100 IU/kg once daily), starting the thrombophilia, two or more gonadotropin testing ($n = 512$)RCT, single center ($n = 83$)With: three or more failedFCT, single center ($n = 83$)With: three or more failed		
center ($n = 5.2$)ICSI women. Without:first day of injections until the pregnancy test. Age: thrombophilia, hormonalinst day of injections until the pregnancy test. Age: 37.1 \pm 4.9 years ($n = 19$)Retrospective observationalWith: two or more failedLMWH was administered at a prophylactic dosage (i.e. enoxaparin 40 mg daily or nadroparin 80/100 IU/kg or dalteparin 80/100 IU/kg once daily), starting the thrombophilia, two or more failed implantationsRCT, single center ($n = 83$)With: three or more failedEnoxaparin 40 mg daily or nadroparin 80/100 IU/kg once day before COH until the day of β-human chorionic gonadotropin testing ($n = 512$)	No treatment.	Not RCT, Age
thrombophilia, hormonal 37.1 ± 4.9 years ($n = 19$)immunologic disorders 37.1 ± 4.9 years ($n = 19$)immunologic disordersLMWH was administered at a prophylactic dosage (i.e.Retrospective observationalWith: two or more failedLMWH was administered at a prophylactic dosage (i.e.analysis, single centerimplantation. Without: bothenoxaparin 40 mg daily or nadroparin 80/100 IU/kg $(n = 569)$ acquired and inheritedor dalteparin 80/100 IU/kg once daily), starting thethrombophilia, two or moreday before COH until the day of β-human chorionicfailed implantationsgonadotropin testing ($n = 512$)RCT, single center ($n = 83$)With: three or more failedEnoxaparin 40 mg/day subcutaneous injections. Age:	Age:	different
Retrospective observationalWith: two or more failed manysis, single centerLMWH was administered at a prophylactic dosage (i.e. analysis, single center $(n = 569)$ with: two or more failed momony acquired and inheritedLMWH was administered at a prophylactic dosage (i.e. enoxaparin 40 mg daily or nadroparin 80/100 IU/kg or dalteparin 80/100 IU/kg once daily), starting the thrombophilia, two or more failed implantationsRCT, single center ($n = 83$)With: three or more failed momon failedEnoxaparin 40 mg day subcutaneous injections. Age:	41.6 ± 3.8 years	between groups.
Retrospective observational with two or more raised LIMWH was administered at a proprivatic goosage (i.e. analysis, single center implantation. Without: both enoxaparin 40 mg daily or nadroparin 80/100 IU/kg ($n = 569$) acquired and inherited or dalteparin 80/100 IU/kg once daily), starting the thrombophilia, two or more day before COH until the day of β-human chorionic failed implantations gonadotropin testing ($n = 512$) With: three or more failed Enoxaparin 40 mg/day subcutaneous injections. Age:	(11 - 10)	
$(n = 569)$ analyse center importation. Writhout, both encodering of neuroparin of neuroparin of the acquired and inherited or dalteparin 80/100 IU/kg once daily), starting the thrombophilia, two or more day before COH until the day of β -human chorionic failed implantations gonadotropin testing $(n = 512)$ RCT, single center $(n = 83)$ With: three or more failed Enoxaparin 40 mg/day subcutaneous injections. Age:	עם הבפתוובוור עם – בלא	
RCT, single center ($n = 83$) With: three or more failed Enoxparing the more failed superimentations and the more failed superimentations and the more failed subcutaneous injections. Age:		
failed implantations gonadotropin testing ($n = 512$) RCT, single center ($n = 83$) With: three or more failed Enoxaparin 40 mg/day subcutaneous injections. Age:		
RCT, single center ($n = 83$) With: three or more failed Enoxaparin 40 mg/day subcutaneous injections. Age:		
incl, single center (n - oc) with times of inor tance children constant to ingrash subcatanteous injections. Acc	No treatment Ade:	\\/ith
$\frac{1}{2} \frac{1}{2} \frac{1}$	אט וובמווובווו. אאב. אסט ו- 13 איייייגי (א – 14)	+hromhoohilio
(Jordan) (/) 29 ± 6.3 years ($n = 4.2$) 29.2 ± 5.1 years ($n = 4.2$)	29.2 ± 6.1 years ($n = 4.1$)	thrombophilla

according to the randomized trials score after quality assessment. The other two studies were either at medium (17) or high (8) risk after quality assessment. These two publications either did not strictly follow the RCT blinding rule or did not report sufficient information for the assessment. In total, the included studies were assessed with a relatively moderate bias.

Funnel plot for all the analyses suggested no evidence of publication bias. The outcomes of pregnancy were considered to be objective and unlikely to be influenced by masking. All studies either had no funding (8) or clearly described the involvement of funding agencies and reported no conflicts of interest.

Primary outcome: live birth rate. Four studies reported LBR as an outcome (10,11,16,17). The total risk ratio using a fixed-effects model was 1.13 with 95% CI 0.88–1.43 (p = 0.34, Figure 3a). Three other studies showed relatively favorable results for LBR in women receiving LMWH treatment compared with placebo or no treatment control, and none of these studies showed significant differences. This meta-analysis showed no significant differences in LBR between LMWH-treated and control groups. Because the outcomes of pregnancy are closely related to number of IVF/ICSI cycles, women with failed IVF/ICSI cycles usually had poorer reproductive outcomes. We further divided the participants into subgroups according to the number of IVF/ICSI cycles. The risk ratio results showed no significant difference in women with two or more failed IVF/ICSI cycles (RR 1.15; 95% CI 0.84–1.58, p = 0.38, Figure 3b). Meanwhile, pooled risk ratios in women with three or more failed IVF/ICSI cycles showed a relative improvement in LBR, but without significant difference (RR 1.36; 95% CI 0.82–2.26, p = 0.24, Figure 3c).

Secondary outcomes. Five studies reported CPR as an outcome. Two studies reported a significant increase in CPR (8,16). However, this meta-analysis found no significant differences in CPR (RR 1.08; 95% CI 0.88–1.32, p = 0.47, Figure 4a). Three studies compared CPR in women with different numbers of IVF/ICSI cycles. However, the risk ratio results showed no significant difference in women either with two or more failed IVF/ICSI cycles (RR 1.17; 95% CI 0.90–1.51, p = 0.23) or with three or more failed IVF/ICSI cycles (RR 1.35; 95% CI 0.93–1.96, p = 0.12, Figure 4b,c). The quality of evidence was assessed at low heterogeneity.

Three papers (10,11,16) reported the MR. This metaanalysis showed less of a trend for MR in the LMWH group, but showed no significant difference (RR 0.58; 95% CI 0.30–1.10, p = 0.09, Figure 5).

Age was another main factor that influenced the success rate of IVF/ICSI. Two studies reported women with different ages (8,10), and the participants were divided




Figure 2. Summary of risk of bias of included studies. Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies (a). Risk of bias summary: review authors' judgments about each risk of bias item for each included study (b). [Color figure can be viewed at wileyonlinelibrary.com]

(a)

	LMW	Н	Contr	ol		Risk ratio		Risk	ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fix	<u>ęd, 95% Cl</u>		
Berker 2011	32	104	30	103	32.5%	1.06 [0.70, 1.60]		-	₽ -		
Lodigiani 2017	25	135	27	131	29.5%	0.90 [0.55, 1.46]		-	-		
Noci 2011	21	73	16	80	16.4%	1.44 [0.82, 2.54]			+		
Urman 2009	26	75	20	75	21.5%	1.30 [0.80, 2.12]		-	+∎		
Total (95% CI)		387		389	100.0%	1.13 [0.88, 1.43]			•		
Total events	104		93								
Heterogeneity: Chi ² =	1.96, <i>df</i> =	3 (p = 0).58); <i>I</i> ² =	0%				<u> </u>	-	+	400
Test for overall effect:	Z = 0.96 (p = 0.3	4)).1 rs [control]	Favors [L	10 _MWH]	100

(b)	LMW	н	Contr	ol		Risk ratio			Risk ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H	. Fixed, 95	% CI	
Berker 2011	32	104	30	103	60.1%	1.06 [0.70, 1.60]					
Urman 2009	26	75	20	75	39.9%	1.30 [0.80, 2.12]			-+∎		
Total (95% CI)		179		178	100.0%	1.15 [0.84, 1.58]			•		
Total events	58		50								
Heterogeneity: Chi ² = (0.40, <i>df</i> =	1 (p = 0	0.53); <i>I</i> ² =	0%							400
Test for overall effect:	Z = 0.88 (p = 0.3	8)				0.01 I	0.1 Favors [cont	rol] Favo	10 rs [LMWH]	100



Figure 3. Forest plot of live birth rate (LBR) in women without thrombophilia treated with in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) by fixed effects model analysis. Pooled risk ratios (RRs) and 95% confidence intervals (Cls) of the association between low-molecular-weight heparin (LMWH) and control groups (a), in women with two or more failed IVF/ICSI cycles (b), and in women with three or more failed IVF/ICSI cycles (c). [Color figure can be viewed at wileyonlinelibrary.com]

into two subgroups according to age: \leq 35 years, >35 years. Our result found no significant differences in the effect of LMWH for maternal age on the CPR. Three studies that reported LMWH were given for oocyte retrieval (11,16,17). We pooled the results, showing no significant differences between the groups (data not shown).

We also used a random-effects model for LBR, CPR and MR meta-analysis and got similar results (see Supporting Information, Figures S1–S3).

Side effects

Three studies observed side effects of LMWH (8,10,11). In general, there were no serious side effects reported in

any study (8,10,11). One study reported five cases of vaginal bleeding or bloody discharge during the therapeutic procedure among the 62 women receiving LMWH treatment, but not serious enough to stop the use of LMWH (8). None of the studies reported developing preeclampsia during the gestational period. There were not enough data to pool the side effect data such as intrauterine growth restriction and preeclampsia outcomes.

Discussion

The current systematic review summarizes the available evidence from RCTs or quasi-RCTs using LMWH as an adjuvant therapy in pregnant women undergoing IVF/ (a)

	LMW	Ή	Contr	ol		Risk ratio	Risk ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Berker 2011	36	104	35	103	28.8%	1.02 [0.70, 1.49]	-
Lodigiani 2017	29	135	35	131	29.1%	0.80 [0.52, 1.24]	
Noci 2011	19	73	16	80	12.5%	1.30 [0.73, 2.33]	- +
Urman 2009	34	75	29	75	23.8%	1.17 [0.80, 1.71]	
Xiong 2015	12	65	8	82	5.8%	1.89 [0.82, 4.35]	+
Total (95% CI)		452		471	100.0%	1.08 [0.88, 1.32]	•
Total events	130		123				
Heterogeneity: Chi ² =	4.22, df =	4(p = 0)	.38); <i>I</i> ² =	5%			
Test for overall effect:	Z = 0.72 (p = 0.47	7)				0.01 0.1 1 10 100 Favors [Control] Favors [LWMH]

(b)

	LMW	н	Contr	ol		Risk ratio		Ris	k ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		<u>M-H, Fi</u>	<u>xed, 95%</u>	CI	
Berker 2011	36	104	35	103	49.4%	1.02 [0.70, 1.49]			- # -		
Urman 2009	34	75	29	75	40.7%	1.17 [0.80, 1.71]					
Xiong 2015	12	65	8	82	9.9%	1.89 [0.82, 4.35]			† ••	-	
Total (95% CI)		244		260	100.0%	1.17 [0.90, 1.51]			•		
Total events	82		72								
Heterogeneity: Chi ² =	1.79, <i>df</i> =	2 (p = 0).41); <i>I</i> ² =	0%			0.01	0.1	1	10	100
Test for overall effect:	Z = 1.19 (p = 0.23	3)					Favors [control]	Favors	[LWMH]	100

(c)

	LMW	н	Contr	ol		Risk ratio	Risk ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Berker 2011	17	48	12	43	38.0%	1.27 [0.69, 2.34]	
Urman 2009	16	37	13	34	40.7%	1.13 [0.64, 1.99]	
Xiong 2015	12	65	8	82	21.3%	1.89 [0.82, 4.35]	+
Total (95% CI)		150		159	100.0%	1.35 [0.93, 1.96]	•
Total events	45		33				
Heterogeneity: Chi ² =	1.04, <i>df</i> = 2	2(p = 0)).59); <i>I</i> ² =	0%			
Test for overall effect:	Z = 1.55 (p = 0.12	2)				0.01 0.1 1 10 100 Favors [control] Favors [LMWH]

Figure 4. Forest plot of clinical pregnancy rate (CPR) in women treated with in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) by fixed effects model analysis. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) of the association between low-molecular-weight heparin (LMWH) and control groups (a), in women with two or more failed IVF/ICSI cycles (b), and in women with three or more failed IVF/ICSI cycles (c). [Color figure can be viewed at wileyonlinelibrary.com]

	LMW	н	Conti	rol		Risk ratio	Risk ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Lodigiani 2017	3	135	8	131	38.5%	0.36 [0.10, 1.34]	
Noci 2011	4	19	3	16	15.4%	1.12 [0.29, 4.29]	_
Urman 2009	6	34	9	29	46.1%	0.57 [0.23, 1.41]	
Total (95% CI)		188		176	100.0%	0.58 [0.30, 1.10]	•
Total events	13		20				
Heterogeneity: Chi ² =	1.43, <i>df</i> = 2	2 (p = 0).49); <i>I</i> ² =	0%			- + + + + + + + + + + + + + + + + + +
Test for overall effect:	Z = 1.68 (p = 0.09	9)				0.01 0.1 1 10 100 Favors [control] Favors [LMWH]

Figure 5. Forest plot of miscarriage rate (MR) of in women treated with in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) women by fixed effects model analysis. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) of the association between low-molecular-weight heparin (LMWH) and control. [Color figure can be viewed at wileyonlinelibrary.com]

ICSI treatment, with the aim to evaluate pregnancy outcomes in non-thrombophilic women. This meta-analysis demonstrated no significant differences in LBR, CPR and MR between the LMWH-treated and control groups. In addition, no significant difference in the number of previous IVF cycles or different age groups was observed.

Compared with previous systematic reviews of LMWH on the outcomes of assisted reproduction, this meta-analysis had more updated data, with different inclusion and exclusion criteria. An extended and systematic search was conducted in the electronic databases and a broad syntax was used, which produced many papers in the search results.

The limitations of this study were that the evidence was assessed to be of moderate quality. Overall, the risk of bias was not sufficiently substantial affecting the results of these included studies. Another limitation of the included studies was lack of exact data on embryo transfer. As most of the RCTs focused on implantation rate, they only reported the percentage instead of the exact number of embryo transfers. This made the pooling and analysis of these data impossible.

The outcomes of IVF/ICSI pregnancies are associated with multifactorial pathophysiology including thrombophilia. Thrombophilia is a condition of the blood with a tendency to clot (20). Studies from animal models have shown that placental thrombosis was closely related to pregnancy loss (21). Reports suggested that it was also closely related to recurrent miscarriages (22-24). Hence, clinicians had begun using anticoagulant therapy, such as LMWH, to improve the pregnancy outcomes. Favorable results with LMWH led to a new question of whether this therapy could be applied to women undergoing IVF treatment for routine clinical use. Studies have shown that administration of aspirin has no positive effect on the implantation and pregnancy rates (25,26). Results of clinical trials suggested that neither aspirin alone nor aspirin combined with LMWH improved LBR compared with the placebo among women with unexplained recurrent miscarriages (27). In fact, evidence showed that this therapy may even increase the risk of prematurity (28). Studies also suggested that LMWH could not reduce the risk of recurrent placenta-mediated pregnancy complications (4). Hence, it is worth pooling the results of completed RCTs to explore the effect of LMWH in non-thrombophilic women on IVF/ICSI outcomes.

This paper was different from previous meta-analysis reports (3,22,29) that included thrombophilic women. Three previous meta-analyses (3,22,29) assessed the efficiency of LMWH in the outcomes of assisted reproduction. Seshadri et al. (3) included five RCT studies and five prospective comparative studies in their review. The treatment group was either heparin or heparin plus aspirin, and thrombophilic participants were also included in the analysis. Seshadri et al. have concluded that the role of adjuvant heparin therapy showed no positive effect during IVF. In 2013, Potdar et al. (29) pooled two RCTs and one quasi-RCT (7,11,17), including women with thrombophilia (7). The pooled risk ratios in women with three or more failed IVF/ICSI cycles showed a significant improvement in the LBR (RR 1.79, p = 0.02) and a reduction in the MR (RR 0.22, p = 0.02) for the LMWH-treated group compared with the control group. This is because the participants pooled in this review had risk bias and with limited number, so the authors discouraged the routine use of LMWH as an adjunctive therapy in women with recurrent implantation failure. In the same year, Akhtar et al. (22) pooled the data of two RCT studies (11,16) and one study (7) with thrombophilic women receiving LMWH for assisted reproduction as a systematic review in the Cochrane database. In 2015, Akhtar et al. (22) summarized their previous work again but without a data update. These results showed no benefit of heparin on pregnancy outcomes. The authors concluded that the evidence does not justify the use of heparin in this context, except for the well-conducted research trials.

There are several reports on the side effects of LMWH administration (4,30). However, these reports also noted that the bleeding showed no differences between the treatment and control groups (4,30). One study (19) using intrauterine injection indicated that intrauterine injection of LMWH was considered a safe intervention without any beneficial effect.

Publication bias affects the results of systematic review. We used funnel plots to analyze for any potential bias. Funnel plots were symmetric, demonstrating no publication bias, with regard to live birth, pregnancy and miscarriage rates.

In conclusion, our results did not support the routine use of LMWH as an adjuvant therapy in non-thrombophilic IVF/ICSI-treated women in terms of pregnancy outcomes. However, there are many factors, such as differences at the time of administration, length of therapy and gestational age at discontinuation of LMWH etc., that might affect the results. Moreover, the included studies were conducted in one center, potentially limiting their external validity. Therefore, these findings need to be further investigated with well-designed, adequately powered double-blinded, randomized, placebo-controlled, multicenter trials.

Funding

This work was supported by the CAMS Initiative for Innovative Medicine (CAMS-I2M2016-I2M-3-007), the

National Natural Science Foundation of China (81470159, 81490745), and the National Major Research Development Program of China (2016YFC1000905). The statements, findings, conclusions and recommendations are those of the authors and do not necessarily reflect the views of these funders.

References

- El-Toukhy T, Campo R, Khalaf Y, Tabanelli C, Gianaroli L, Gordts SS, et al. Hysteroscopy in recurrent in-vitro fertilisation failure (TROPHY): a multicentre, randomised controlled trial. Lancet. 2016;387:2614–21.
- Nelson SM, Greer IA. The potential role of heparin in assisted conception. Hum Reprod Update. 2008;14: 623–45.
- 3. Seshadri S, Sunkara SK, Khalaf Y, El-Toukhy T, Hamoda H. Effect of heparin on the outcome of IVF treatment: a systematic review and meta-analysis. Reprod Biomed Online. 2012;25:572–84.
- Rodger MA, Gris JC, de Vries JIP, Martinelli I, Rey É, Schleussner E, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016;388:2629–41.
- Sobel ML, Kingdom J, Drewlo S. Angiogenic response of placental villi to heparin. Obstet Gynecol. 2011;117:1375– 83.
- Grandone E, Villani M, Tiscia GL, Dentali F, Colaizzo D, Cappucci F, et al. Clinical pregnancies and live births in women approaching ART: a follow-up analysis of 157 women after thrombophilia screening. Thromb Res. 2014;133:168–72.
- Qublan H, Amarin Z, Dabbas M, Farraj AE, Beni-Merei Z, Al-Akash H, et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum Fertil (Camb). 2008;11:246–53.
- Xiong ZF, Dang XH, Li B, Wang LY. Low-molecularweight heparin in women with repeated implantation failure (in Chinese). J Pract Obstet Gynecol. 2015;31:614– 7.
- Lodigiani C, Di Micco P, Ferrazzi P, Librè L, Arfuso V, Polatti F, et al. Low-molecular-weight heparin in women with repeated implantation failure. Womens Health (Lond). 2011;7:425–31.
- Lodigiani C, Dentali F, Banfi E, Ferrazzi P, Libre L, Quaglia I, et al. The effect of parnaparin sodium on in vitro fertilization outcome: a prospective randomized controlled trial. Thromb Res. 2017;159:116–21.
- Urman B, Ata B, Yakin K, Alatas C, Aksoy S, Mercan R, et al. Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial. Hum Reprod. 2009;24:1640–7.

- 12. Fishel S, Baker D, Elson J, Ragunath M, Atkinson G, Shaker A, et al. Precision medicine in assisted conception: a multicenter observational treatment cohort study of the Annexin A5 M2 Haplotype as a biomarker for antithrombotic treatment to improve pregnancy outcome. EBioMedicine. 2016;10:298–304.
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
- 14. Higgins JPT, Sterne JAC, Savović J, Page MJ, Hróbjartsson A, Boutron I, et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V (eds). Cochrane methods. Cochrane Database of Systematic Reviews. 2016;10(Suppl 1).
- Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
- Noci I, Milanini MN, Ruggiero M, Papini F, Fuzzi B, Artini PG. Effect of dalteparin sodium administration on IVF outcome in non-thrombophilic young women: a pilot study. Reprod Biomed Online. 2011;22:615–20.
- Berker B, Taşkin S, Kahraman K, Taşkin EA, Atabekoğlu C, Sönmezer M. The role of low-molecular-weight heparin in recurrent implantation failure: a prospective, quasirandomized, controlled study. Fertil Steril. 2011;95:2499–502.
- Hamdi K, Danaii S, Farzadi L, Abdollahi S, Chalabizadeh A, Abdollahi Sabet S. The role of heparin in embryo implantation in women with recurrent implantation failure in the cycles of assisted reproductive techniques (without history of thrombophilia). J Family Reprod Health. 2015;9:59–64.
- Kamel AM, El-Faissal Y, Aboulghar M, Mansour R, Serour GI, Aboulghar M. Does intrauterine injection of lowmolecular-weight heparin improve the clinical pregnancy rate in intracytoplasmic sperm injection. Clin Exp Reprod Med. 2016;43:247–52.
- Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010;149:209–20.
- Tong MH, Jiang H, Liu P, Lawson JA, Brass LF, Song WC. Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nat Med. 2005;11:153–9.
- 22. Akhtar MA, Sur S, Raine-Fenning N, Jayaprakasan K, Thornton JG, Quenby S. Heparin for assisted reproduction. Cochrane Database Syst Rev. 2013;8: CD009452.
- 23. Folkeringa N, Brouwer JL, Korteweg FJ, Veeger NJ, Erwich JJ, Holm JP, et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol. 2007;136:656–61.
- 24. Rand JH, Wu XX, Guller S, Gil J, Guha A, Scher J, et al. Reduction of annexin-V (placental anticoagulant protein-I)

on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol. 1994;171:1566–72.

- 25. Dentali F, Ageno W, Rezoagli E, Rancan E, Squizzato A, Middeldorp S, et al. Low-dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-analysis of the literature. J Thromb Haemost. 2012;10:2075–85.
- 26. Duvan CI, Ozmen B, Satiroglu H, Atabekoglu CS, Berker B. Does addition of low-dose aspirin and/or steroid as a standard treatment in nonselected intracytoplasmic sperm injection cycles improve in vitro fertilization success? A randomized, prospective, placebo-controlled study. J Assist Reprod Genet. 2006;23:15–21.
- Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyák K, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362:1586–96.
- Laskin CA, Bombardier C, Hannah ME, Mandel FP, Ritchie JW, Farewell V, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 1997;337:148–53.
- 29. Potdar N, Gelbaya TA, Konje JC, Nardo LG. Adjunct lowmolecular-weight heparin to improve live birth rate after recurrent implantation failure: a systematic review and meta-analysis. Hum Reprod Update. 2013;19:674–84.
- 30. Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014;384:1673–83.
- Siristatidis C, Dafopoulos K, El-Khayat W, Salamalekis G, Anifandis G, Vrantza T, et al. Administration of prednisolone and low molecular weight heparin in patients with repeated implantation failures: a cohort study. Gynecol Endocrinol. 2018;34:136–9.
- Shirlow R, Healey M, Volovsky M, MacLachlan V, Vollenhoven B. The effects of adjuvant therapies on embryo transfer success. J Reprod Infertil. 2017;18:368–78.
- 33. Tormene D, Esposito F, Falcone L, Viganó F, Gangemi M, Nardelli GB, et al. Effect of prophylaxis with lmwh on

implantation in women undergoing assisted reproductive procedures (IVF or ICSI): a prospective randomized study. J Thromb Haemost. 2015;13:488.

34. Siristatidis C, Chrelias C, Creatsa M, Varounis C, Vrachnis N, Iliodromiti Z, et al. Addition of prednisolone and heparin in patients with failed IVF/ICSI cycles: a preliminary report of a clinical trial. Hum Fertil (Camb). 2013;16:207–10.

Supporting information

Additional Supporting Information may be found in the online version of this article:

Figure S1. Forest plot of live birth rate (LBR) of women without thrombophilia treated with in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) by random effects model analysis. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) of the association between low-molecular-weight heparin (LMWH) and control groups (a), in women with two or more failed IVF/ICSI cycles and (b), and in women with three or more failed IVF/ICSI cycles (c).

Figure S2. Forest plot of clinical pregnancy rate (CPR) of women treated with in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) by random effects model analysis. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) of the association between low-molecularweight heparin (LMWH) and control women (a), in women with two or more failed IVF/ICSI cycles (b), and in women with three or more failed IVF/ICSI cycles (c).

Figure S3. Forest plot of miscarriage rate (MR) of women tread with in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) by random effects model analysis. Pooled risk ratios (RRs) and 95% confidence intervals (CIS) of the association between low-molecular-weight heparin (LMWH) and control.

Table S1. Supporting PRISMA checklist.**Table S2.** Search strategy.